

Antibiotic resurrection: Taking the path of least resistance

SMi proudly presents the return of their annual Superbugs & Superdrugs conference taking place in London on the 16th-17th March 2016.

LONDON, UNITED KINGDOM, January 5, 2016
/EINPresswire.com/ -- SMi are delighted to have Professor Conrad Lichtenstein, Chief Scientific Officer from Nemesis Bioscience Ltd, deliver a keynote address at the 18th annual conference on [Superbugs & Superdrugs](#).

Lichtenstein has held a variety of positions with elite institutions such as: University of Washington, Imperial College London, and Queen Mary University of London. Following his research at these establishments and prior to his current role, Professor Conrad worked for Population Genetics Technology where he developed methods to enable the rapid, low-cost, simultaneous analysis of

candidate genes in multiple genomes and the identification of rare variants in mixed DNA samples from human, plant and microbial sources.

Entitled 'Antibiotic resurrection: Taking the path of least resistance' Professor Conrad Lichtenstein's presentation will give insight into achieving antibiotic sensitivity and resistance prevention; discuss clinical applications; and explore delivery options for companion therapeutics in Nemesis Symbiotics.

“

Now running for almost two decades 'Superbugs and Superdrugs' will once again play host to an audience of anti-infective experts, providing a focal point to discuss the latest clinical advancements

SMi Group

Now running for almost two decades '[Superbugs and Superdrugs](#)' will once again play host to an audience of anti-infective experts, providing a focal point to discuss the latest clinical advancements and funding opportunities. Joining Professor Lichtenstein will be leading industry experts from the likes of European Commission, BARDA, Cembra Pharmaceuticals and many more.



The full speaker line-up and detailed conference agenda is available to download online at www.superbugssuperdrugs.com/EIN

Running alongside the conference are two interactive [pre-conference workshops](#). The first will be led by Sam Whitehouse the Chief Operating Officer from QuantuMDx Group Ltd. and is entitled 'Rapid Diagnostic Tools for Infectious Diseases'. The second workshop to take place, 'Making a Material Difference to Healthcare' will be led by ACT Surfaces Ltd's Director, Andrew Cross.

Further information on the workshops and their leaders can be found online at www.superbugssuperdrugs.com/EIN

18th annual conference: Superbugs & Superdrugs
16-17 March 2016
Holiday Inn Kensington Forum, London UK
www.superbugssuperdrugs.com/EIN

--- END ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2016 IPD Group, Inc. All Right Reserved.